Stockscreener 앱 받기
102.94
1.49%
1.4658
전일 마감가:
$101.47
열려 있는:
$102.02
하루 거래량:
45,864
Relative Volume:
0.08
시가총액:
$8.13B
수익:
-
순이익/손실:
$-425.38M
주가수익비율:
-17.59
EPS:
-5.8504
순현금흐름:
$-275.21M
1주 성능:
+3.92%
1개월 성능:
-0.70%
6개월 성능:
+7.42%
1년 성능:
+51.02%
1일 변동 폭
$100.64
$105.73
1주일 범위
$97.77
$105.73
52주 변동 폭
$63.55
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
102.98 | 8.01B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
426.82 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.93 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.09 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.50 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.08 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Wells Fargo | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com
Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat
Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com
Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan
Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC - Yahoo Finance
NUVL (NASDAQ) Form 144: Affiliate to sell 16,500 shares via option exercise - Stock Titan
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal (NASDAQ:NUVL) - Seeking Alpha
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - BioSpace
Guardant Health partners with Nuvalent on diagnostic tests By Investing.com - Investing.com South Africa
Guardant Health partners with Nuvalent on diagnostic tests - Investing.com
Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent - Bitget
CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Pictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $4.70 Million Position in Nuvalent, Inc. $NUVL - MarketBeat
[ARS] Nuvalent, Inc. SEC Filing - Stock Titan
[DEF 14A] Nuvalent, Inc. Definitive Proxy Statement - Stock Titan
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a Promising 36% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Leerink Partners Maintains Nuvalent (NUVL) Outperform Recommendation - MSN
Canaccord Genuity Remains a Buy on Nuvalent (NUVL) - The Globe and Mail
Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial Data - Yahoo Finance
NUVL (Nuvalent Inc.) reports wider-than-expected Q4 2025 loss, shares edge 0.26% lower in post-earnings trading.Competitive Risk - Xã Thanh Hà
Trading the Move, Not the Narrative: (NUVL) Edition - Stock Traders Daily
Nuvalent stock presents AACR data ahead of September PDUFA By Investing.com - Investing.com Australia
Nuvalent stock presents AACR data ahead of September PDUFA - Investing.com
NUVL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $155 - GuruFocus
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting - The Malaysian Reserve
HC Wainwright Reaffirms Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent, Inc. (NUVL) Stock Analysis: Unveiling a 32% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Nuvalent data show activity of ROS1 inhibitor after next-gen TKIs - The Pharma Letter
Benjamin Lane Net Worth (2026) - GuruFocus
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 - Sahm
Nuvalent presents zidesamtinib data in pre-treated lung cancer By Investing.com - Investing.com Australia
Nuvalent presents zidesamtinib data in pre-treated lung cancer - Investing.com
Nuvalent, IncNuvalent Anticipates U.S. Commercial Launch Of Zidesamtinib In 2026 - TradingView
Nuvalent (NUVL) Stock Industry Rotation (Slow Drop) 2026-04-16Institutional Grade Picks - UBND thành phố Hải Phòng
Does FDA Filing For Neladalkib’s ALK-Targeted Lung Cancer Therapy Change The Bull Case For Nuvalent (NUVL)? - simplywall.st
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Nuvalent (NUVL) CSO Pelish sells $323k in shares By Investing.com - Investing.com Australia
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvalent Inc 주식 (NUVL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
May 01 '26 |
Sale |
99.00 |
11,430 |
1,131,600 |
85,533 |
| Miller Deborah Ann | Chief Legal Officer |
Apr 30 '26 |
Option Exercise |
6.89 |
5,500 |
37,895 |
65,134 |
| Miller Deborah Ann | Chief Legal Officer |
Apr 30 '26 |
Sale |
99.22 |
5,500 |
545,691 |
59,634 |
| Noci Darlene | Chief Development Officer |
Apr 29 '26 |
Option Exercise |
27.85 |
5,500 |
153,175 |
63,617 |
| Noci Darlene | Chief Development Officer |
Apr 29 '26 |
Sale |
99.55 |
5,500 |
547,524 |
58,117 |
0.78%
3.01%
자본화:
|
볼륨(24시간):